Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United States Food and Drug Administration (FDA).

Flora Mulkey,Kunthel By,Marc Robert Theoret,Virginia Ellen Maher,Richard Pazdur,Rajeshwari Sridhara

Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United States Food and Drug Administration (FDA).

2019

Flora Mulkey
Kunthel By
Marc Robert Theoret
Virginia Ellen Maher
Richard Pazdur
Rajeshwari Sridhara

2516Background: Many studies exhibit what seems to be dis-proportionately higher early mortality (EM) in anti-PD-1/PD-L1 containing arms (IO) when compared to active control arms (AC), resulting in...

Keywords:

PD-L1
Physical therapy
Drug
Randomized controlled trial
Antibody
Medicine
Internal medicine
food and drug administration
anti pd 1
active control

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations